新生儿先天性代谢病高氨血症肾脏替代治疗的多中心回顾性结局分析
该多中心回顾性分析纳入2000至2015年美国9家儿童医院的51例确诊先天性代谢病新生儿,评估因高氨血症接受肾脏替代治疗(RRT)的结局。存活33例(65%),死亡18例;血液透析、除高氨血症外存在1项以上RRT指征及RRT期间并发症均为死亡危险因素,校正多因素后血液透析死亡风险高于连续性肾脏替代治疗(CRRT)。作者据此支持新生儿高氨血症采用CRRT。
要点
- 血液透析、多项RRT指征及RRT期间并发症与死亡风险升高相关
- 作者支持新生儿高氨血症使用连续性肾脏替代治疗
核心结论
- 多中心回顾性分析支持新生儿高氨血症采用连续性肾脏替代治疗(CRRT)。
研究设计与样本
- 回顾性分析2000至2015年美国9家儿童医院51例确诊先天性代谢病并接受RRT的新生儿。
主要发现
- 存活33例(65%),死亡18例;存活者与死亡者入院日龄中位数均为3天。
- 存活者与死亡者峰值氨及入院时氨水平无显著差异。
- 血液透析、除高氨血症外存在1项以上RRT指征、RRT期间并发症均为死亡危险因素。
临床怎么用
- 对因先天性代谢病高氨血症需RRT的新生儿,可优先考虑连续性肾脏替代治疗。
- 关注除高氨血症外的RRT指征及RRT期间并发症,作为死亡风险评估因素。
- 可参考作者基于RRT开始时已知变量建立的生存预测模型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the outcomes of neonates in a contemporary multi-institutional cohort who receive renal replacement therapy (RRT) for hyperammonemia. STUDY DESIGN: We performed a retrospective analysis of 51 neonatal patients with confirmed inborn errors of metabolism that were treated at 9 different children's hospitals in the US between 2000 and 2015. RESULTS: Twenty-nine patients received hemodialysis (57%), 21 patients received continuous renal replacement therapy (41%), and 1 patient received peritoneal dialysis (2%). The median age at admission of both survivors (n = 33 [65%]) and nonsurvivors (n = 18) was 3 days. Peak ammonia and ammonia at admission were not significantly different between survivors and nonsurvivors. Hemodialysis, having more than 1 indication for RRT in addition to hyperammonemia, and complications during RRT were all risk factors for mortality. After accounting for multiple patient factors by multivariable analyses, hemodialysis was associated with a higher risk of death compared with continuous renal replacement therapy. When clinical factors including evidence of renal dysfunction, number of complications, concurrent extracorporeal membrane oxygenation, vasopressor requirement, and degree of hyperammonemia were held constant in a single Cox regression model, the hazard ratio for death with hemodialysis was 4.07 (95% CI 0.908-18.2, P value = .067). To help providers caring for neonates with hyperammonemia understand their patient's likelihood of survival, we created a predictive model with input variables known at the start of RRT. CONCLUSIONS: Our large, multicenter retrospective review supports the use of continuous renal replacement therapy for neonatal hyperammonemia.
引用
- Ames EG, Powell C, Engen RM, et al. Multisite Retrospective Review of Outcomes in Renal Replacement Therapy for Neonates with Inborn Errors of Metabolism. J Pediatr. 2022. PMID: 35358588. doi:10.1016/j.jpeds.2022.03.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。